Adriamycin (NSC 123127) in the treatment of alkylator resistant multiple myeloma: a pilot study

D. S. Alberts, S. E. Salmon

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Adriamycin was given in a dose of 25 to 45 mg/m2 of bodrface area to 9 patients with multiple myeloma who had failed to respond to intermittent therapy with melphalan and prednisone. Three patients had evidence of clinical remission and in 2 of them there was a 60% decrease in total body myeloma cell number. However, remissions were of short duration (3 mth in 2 patients and over 10 months in another patient) and bone marrow suppression was moderately severe. Adriamycin may prove more useful in myeloma therapy when combined with melphalan or cyclophosphamide during the initial attempt at remission induction.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalCANCER CHEMOTHER.REP.
Volume59
Issue number2
StatePublished - Dec 1 1975

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adriamycin (NSC 123127) in the treatment of alkylator resistant multiple myeloma: a pilot study'. Together they form a unique fingerprint.

Cite this